Home / Resources / Strategic Leadership resources

战略领导力

最新资源

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Data Fabrics in Pharma: Connecting Data for Better Decisions

Data Fabrics in Pharma: Connecting Data for Better Decisions

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

精选资源

Certara Welcomes Arjun Bedi to its Board of Directors

Certara Welcomes Arjun Bedi to its Board of Directors 

Upcoming strategic leadership webinars

网络研讨会

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

2026 年 4 月 23 日 – 3-4pm (JST) and 10-11am (CET)

网络研讨会

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

2026 年 5 月 28 日 – 3-4pm (JST) and 10-11am (CET)

Popular resources

Certara Near-Term Emissions Reduction Target Approved by Science Based Targets Initiative to Reduce Environmental Impact

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

网络研讨会

Building Trust in Data – Transparency, Traceability, and the Human Element

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Certara Simcyp® Simulator 成果成功替代慢性髓性白血病（CML）药物 asciminib 的 10 项人体试验

Apotekarsocieteten 临床药理学策略在药物开发中的应用

在以下活动中与我们的专家会面

International PBPK Conference

2026 年 4 月 21 - 24 日

Asembia AXS26 Summit

April 26 - 30, 2026 – Las Vegas, NV

ISPOR International Annual Conference 2026

May 17 - 20, 2026 – Philadelphia, PA

All Strategic Leadership resources

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Data Fabrics in Pharma: Connecting Data for Better Decisions

Certara Products, Certara.AI, Drug Development, Blog

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, New Approach Methodologies (NAMs), Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Certara Services, Clinical Pharmacology, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Blog

Building Trust in Data – Transparency, Traceability, and the Human Element

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Drug Development, Webinar

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Certara Services, Clinical Trials, Drug Development, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Certara Services, Clinical Pharmacology, Drug Development, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Conference

Marbach DDI Workshop 2026

Certara Products - Simcyp, Drug-Drug Interactions (DDI), Modeling and Simulation - PBPK, Conference

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Rare and Neglected Diseases, Blog

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Strong starts, confident finishes: Optimizing first-in-human strategies for antibody–drug conjugates (ADCs)

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Modeling and Simulation, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

1
2
3
……
11
›

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software